Lise Tarnow

List of Publications by Year
in descending order

243 papers	13,810 citations	14655 66 h-index	27406 106 g-index
246 all docs	246 docs citations	246 times ranked	14119 citing authors

#	Article	IF	Citations
1	Comparison of treatment with insulin degludec and glargine <scp>U100</scp> in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The <scp>HypoDeg</scp> randomized, controlled, openâ€label, crossover trial. Diabetes, Obesity and Metabolism, 2022, 24, 257-267.	4.4	6
2	Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. Free Radical Biology and Medicine, 2022, 178, 18-25.	2.9	1
3	Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. Diabetes Technology and Therapeutics, 2022, 24, 643-654.	4.4	6
4	Visitâ€toâ€visit variability of clinical risk markers in relation to longâ€term complications in type 1 diabetes. Diabetic Medicine, 2021, 38, e14459.	2.3	7
5	Effect of 12â€week continuous positive airway pressure therapy on glucose levels assessed by continuous glucose monitoring in people with type 2 diabetes and obstructive sleep apnoea; a randomized controlled trial. Endocrinology, Diabetes and Metabolism, 2021, 4, e00148.	2.4	9
6	Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Osteoporosis International, 2021, 32, 1837-1848.	3.1	8
7	Improving Diabetes Self-management by Providing Continuous Positive Airway Pressure Treatment to Patients With Obstructive Sleep Apnea and Type 2 Diabetes: Qualitative Exploratory Interview Study. JMIR Formative Research, 2021, 5, e27062.	1.4	1
8	Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. Cardiovascular Diabetology, 2020, 19, 150.	6.8	11
9	Association between severe diabetic retinopathy and lectin pathway proteins â€“ an 18-year follow-up study with newly diagnosed type 1 diabetes patients. Immunobiology, 2020, 225, 151939.	1.9	3
10	Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107681.	2.3	1
11	Effect of Metformin vs. Placebo in Combination with Insulin Analogues on Bone Markers P1NP and CTX in Patients with Type 2 Diabetes Mellitus. Calcified Tissue International, 2020, 107, 160-169.	3.1	7
12	Effect of 12Âweeks continuous positive airway pressure on day and night arterial stiffness and blood pressure in patients with type 2 diabetes and obstructive sleep apnea: A randomized controlled trial. Journal of Sleep Research, 2020, 29, e12978.	3.2	7
13	The impact of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	4.4	16
14	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
15	Prediction of In-Hospital Pressure Ulcer Development. Advances in Wound Care, 2019, 8, 1-6.	5.1	18
16	Validation of an Algorithm for Predicting Hypoglycemia From Continuous Glucose Measurements and Heart Rate Variability Data. Journal of Diabetes Science and Technology, 2019, 13, 1178-1179.	2.2	3
17	The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design. BMC Endocrine Disorders, 2019, 19, 78.	2.2	10
18	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2019, 42, 1512-1520.	8.6	77

#	Article	IF	Citations
19	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 2019, 10, 242.	3.5	5
20	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	2.1	18
21	Effect of Insulin Analogs on Frequency of Nonâ€“Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucoseâ€”The HypoAna Trial. Diabetes Technology and Therapeutics, 2018, 20, 247-256.	4.4	17
22	LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 870-878.	11.4	95
23	Arterial stiffness in people with Type 2 diabetes and obstructive sleep apnoea. Diabetic Medicine, 2018, 35, 1391-1398.	2.3	6
24	The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporosis International, 2018, 29, 2517-2526.	3.1	24
25	Prediction of excessive weight gain in insulin treated patients with type 2 diabetes. Journal of Diabetes, 2017, 9, 325-331.	1.8	11
26	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. Diabetes Care, 2017, 40, e32-e33.	8.6	4
27	Are Changes in Heart Rate Variability During Hypoglycemia Confounded by the Presence of Cardiovascular Autonomic Neuropathy in Patients with Diabetes?. Diabetes Technology and Therapeutics, 2017, 19, 91-95.	4.4	11
28	Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemiaâ€prone people with Type 1 diabetes. Diabetic Medicine, 2017, 34, 625-631.	2.3	14
29	Hypoglycemia-Associated EEG Changes Following Antecedent Hypoglycemia in Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2017, 19, 85-90.	4.4	14
30	Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovascular Diabetology, 2017, 16, 55.	6.8	47
31	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. Diabetes, 2017, 66, 2278-2283.	0.6	63
32	Incident microalbuminuria and complement factor mannanâ€binding lectinâ€associated protein 19 in people with newly diagnosed type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2895.	4.0	6
33	Obstructive sleep apnoea is frequent in patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 156-161.	2.3	27
34	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 734-738.	4.4	16
35	Readmission to hospital of medical patients â€“ A cohort study. European Journal of Internal Medicine, 2017, 46, 19-24.	2.2	13
36	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Kidney International, 2017, 92, 1242-1248.	5.2	24

#	Article	IF	Citations
37	Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy. Journal of Diabetes and Its Complications, 2017, 31, 1389-1393.	2.3	11
38	The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial. Diabetes Research and Clinical Practice, 2017, 123, 143-148.	2.8	4
39	Effect of liraglutide, a glucagonâ€like peptideâ€1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)â€”a multicentre, doubleâ€blind, randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	7.1	343
40	Reduced Inspiratory Muscle Strength in Patients with Type 2 Diabetes Mellitus and Obstructive Sleep Apnoea. Journal of Diabetes Research, 2017, 2017, 1-6.	2.3	4
41	Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies. Cardiovascular Diabetology, 2017, 16, 139.	6.8	27
42	The LeucoPatchÂ® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial. Trials, 2017, 18, 469.	1.6	15
43	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. Diabetes, 2016, 65, 239-254.	0.6	41
44	Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open, 2016, 6, e008377.	1.9	11
45	Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitusâ€”the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open, 2016, 6, e008376.	1.9	30
46	Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with typeÂ1 diabetes prone to severe hypoglycaemia: The HypoAna trial. Diabetes and Metabolism, 2016, 42, 249-255.	2.9	25
47	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1603-1608.	2.3	6
48	Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Current Medical Research and Opinion, 2016, 32, 1719-1725.	1.9	6
49	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 221-232.	11.4	127
50	Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. Immunologic Research, 2016, 64, 55-63.	2.9	37
51	Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1036-1045.	1.7	6
52	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. Journal of Diabetes Research, 2015, 2015, 1-11.	2.3	18
53	Infrared thermographic assessment of changes in skin temperature during hypoglycaemia in patients with type 1 diabetes. Diabetologia, 2015, 58, 1898-1906.	6.3	9
54	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open, 2015, 5, e007791-e007791.	1.9	12

#	Article	IF	Citations
55	Vitamin D, carotid intimaâ€“media thickness and bone structure in patients with type 2 diabetes. Endocrine Connections, 2015, 4, 128-135.	1.9	13
56	Use of an autologous leucocyte and platelet-rich fibrin patch on hard-to-heal DFUs: a pilot study. Journal of Wound Care, 2015, 24, 172-178.	1.2	36
57	ACE genotype, phenotype and all-cause mortality in different cohorts of patients with type 1 diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 374-381.	1.7	3
58	Effect of Continuous Glucose Monitoring Accuracy on Cliniciansâ€™ Retrospective Decision Making in Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1092-1102.	2.2	2
59	Glycemic Variability Is Associated With Reduced Cardiac Autonomic Modulation in Women With Type 2 Diabetes. Diabetes Care, 2015, 38, 682-688.	8.6	25
60	The Degree of Autonomic Modulation Is Associated With the Severity of Microvascular Complications in Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 681-686.	2.2	8
61	Combining Information of Autonomic Modulation and CGM Measurements Enables Prediction and Improves Detection of Spontaneous Hypoglycemic Events. Journal of Diabetes Science and Technology, 2015, 9, 132-137.	2.2	28
62	Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension. Journal of Human Hypertension, 2015, 29, 28-32.	2.2	11
63	Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. Diabetic Medicine, 2015, 32, 1104-1109.	2.3	14
64	Hypoglycemia-Associated Changes in the Electroencephalogram in Patients With Type 1 Diabetes and Normal Hypoglycemia Awareness or Unawareness. Diabetes, 2015, 64, 1760-1769.	0.6	33
65	<scp>ACTH</scp> stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia. Clinical Endocrinology, 2015, 82, 155-156.	2.4	1
66	Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabetic Medicine, 2015, 32, 374-381.	2.3	35
67	Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study. Diabetes Care, 2015, 38, 1898-1903.	8.6	22
68	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3032-3040.	3.6	32
69	SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. Diabetologia, 2015, 58, 543-548.	6.3	43
70	Model Study of the Pressure Build-Up during Subcutaneous Injection. PLoS ONE, 2014, 9, e104054.	2.5	41
71	A Novel Algorithm for Prediction and Detection of Hypoglycemia Based on Continuous Glucose Monitoring and Heart Rate Variability in Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2014, 8, 731-737.	2.2	73
72	Accuracy Evaluation of a New Real-Time Continuous Glucose Monitoring Algorithm in Hypoglycemia. Diabetes Technology and Therapeutics, 2014, 16, 667-678.	4.4	18

#	Article	IF	Citations
73	Evaluation of an Algorithm for Retrospective Hypoglycemia Detection Using Professional Continuous Glucose Monitoring Data. Journal of Diabetes Science and Technology, 2014, 8, 117-122.	2.2	17
74	A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	g.9	22
75	Cardiovascular Autonomic Neuropathy Is Associated With Macrovascular Risk Factors in Type 2 Diabetes. Journal of Diabetes Science and Technology, 2014, 8, 874-880.	2.2	19
76	At least one in three people with TypeÂ2 diabetes mellitus referred to a diabetes centre has symptomatic obstructive sleep apnoea. Diabetic Medicine, 2014, 31, 1460-1467.	2.3	32
77	Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatmentâ€“resistant hypertension. Journal of the American Society of Hypertension, 2014, 8, 872-881.	2.3	45
78	Carotid intima-media thickness is reduced 12months after gastric bypass surgery in obese patients with type 2 diabetes or impaired glucose tolerance. Journal of Diabetes and Its Complications, 2014, 28, 517-522.	2.3	23
79	Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 553-561.	11.4	83
80	Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. Diabetologia, 2014, 57, 1143-1153.	6.3	50
81	Novel genetic susceptibility loci for diabetic end-stage renal disease identified through robust naive Bayes classification. Diabetologia, 2014, 57, 1611-1622.	6.3	19
82	Hypoglycaemia and QT interval prolongation in type 1 diabetes â€“ bridging the gap between clamp studies and spontaneous episodes. Journal of Diabetes and Its Complications, 2014, 28, 723-728.	2.3	23
83	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia, 2013, 56, 1845-1855.	6.3	44
84	Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia, 2013, 56, 298-310.	6.3	119
85	CD2AP is associated with end-stage renal disease in patients with type 1 diabetes. Acta Diabetologica, 2013, 50, 887-897.	2.5	8
86	Real-Time Hypoglycemia Detection from Continuous Glucose Monitoring Data of Subjects with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 538-543.	4.4	29
87	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 604-608.	2.3	16
88	A phase 2a, randomized, doubleâ€blind 28â€day study of TZPâ€102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology and Motility, 2013, 25, e140-50.	3.0	76
89	Soccer Training Improves Cardiac Function in Men with Type 2 Diabetes. Medicine and Science in Sports and Exercise, 2013, 45, 2223-2233.	0.4	54
90	Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus. Journal of Hypertension, 2013, 31, 2094-2102.	0.5	120

#	Article	IF	Citations
91	Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2013, 24, 1537-1543.	6.1	66
92	Nocturnal Continuous Glucose Monitoring: Accuracy and Reliability of Hypoglycemia Detection in Patients with Type 1 Diabetes at High Risk of Severe Hypoglycemia. Diabetes Technology and Therapeutics, 2013, 15, 371-377.	4.4	42
93	Professional Continuous Glucose Monitoring in Subjects with Type 1 Diabetes: Retrospective Hypoglycemia Detection. Journal of Diabetes Science and Technology, 2013, 7, 135-143.	2.2	21
94	Influence of Erythropoietin on Cognitive Performance during Experimental Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Randomized Cross-Over Trial. PLoS ONE, 2013, 8, e59672.	2.5	22
95	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. PLoS Genetics, 2012, 8, e1002921.	3.5	216
96	Paper Electrocardiograph Strips May Contain Overlooked Clinical Information in Screen-Detected Type 2 Diabetes Patients. Journal of Diabetes Science and Technology, 2012, 6, 74-80.	2.2	5
97	Screening for Diabetic Cardiac Autonomic Neuropathy Using a New Handheld Device. Journal of Diabetes Science and Technology, 2012, 6, 965-972.	2.2	27
98	Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12Âyear follow-up study. Diabetologia, 2012, 55, 2489-2493.	6.3	29
99	Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Research and Clinical Practice, 2012, 96, 17-23.	2.8	51
100	A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design. BMC Endocrine Disorders, 2012, 12, 10.	2.2	18
101	SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes. Diabetologia, 2012, 55, 2386-2393.	6.3	21
102	Review of Genetic Association in the SOD2 Gene with Chronic Kidney Disease: Case-Control Studies and Meta-Analysis Confirm Association with Diabetic Nephropathy. Nephrology Research & Reviews, 2012, 4, 51-54.	0.2	2
103	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids, 2012, 42, 1627-1639.	2.7	22
104	Prevalence of gastroparesis-related symptoms in an unselected cohort of patients with Type 1 diabetes. Journal of Diabetes and Its Complications, 2012, 26, 89-93.	2.3	33
105	Evaluation of placental growth factor and soluble Fmsâ€like tyrosine kinase 1 as predictors of allâ€cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. Diabetic Medicine, 2012, 29, 337-344.	2.3	14
106	Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. Diabetic Medicine, 2012, 29, 990-994.	2.3	37
107	Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. Digestive and Liver Disease, 2011, 43, 73-77.	0.9	14
108	A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women. Molecular Genetics and Metabolism, 2011, 103, 66-70.	1.1	13

#	Article	IF	Citations
109	Experimental testing of skin reactions to insulin detemir in diabetes patients naÃ¯ve to insulin detemir. Skin Research and Technology, 2011, 17, 411-419.	1.6	4
110	The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. Journal of Negative Results in BioMedicine, 2011, 10, 4.	1.4	7
111	Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy. Nephron Clinical Practice, 2011, 118, c309-c314.	2.3	8
112	Genetic Examination of SETD7 and SUV39H1/H2 Methyltransferases and the Risk of Diabetes Complications in Patients With Type 1 Diabetes. Diabetes, 2011, 60, 3073-3080.	0.6	62
113	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation, 2011, 26, 3242-3249.	0.7	24
114	Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes Care, 2011, 34, 442-447.	8.6	202
115	Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. European Journal of Endocrinology, 2011, 164, 371-379.	3.7	15
116	Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes. PLoS ONE, 2011, 6, e24053.	2.5	12
117	Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia, 2010, 53, 45-48.	6.3	76
118	QT interval prolongation during spontaneous episodes of hypoglycaemia in type 1 diabetes: the impact of heart rate correction. Diabetologia, 2010, 53, 2036-2041.	6.3	52
119	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. Diabetologia, 2010, 53, 2562-2568.	6.3	19
120	Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients. Clinical Proteomics, 2010, 6, 105-114.	2.1	28
121	Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Science, 2010, 8, 4.	1.7	36
122	Carotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study. Cardiovascular Diabetology, 2010, 9, 40.	6.8	33
123	Finding diabetic nephropathy biomarkers in the plasma peptidome by highâ€throughput magnetic bead processing and MALDIâ€TOFâ€MS analysis. Proteomics - Clinical Applications, 2010, 4, 697-705.	1.6	20
124	Neutrophil Gelatinaseâ€Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a crossâ€sectional study and the effects of lisinopril. Diabetic Medicine, 2010, 27, 1144-1150.	2.3	111
125	Osteoprotegerin and Mortality in Type 2 Diabetic Patients. Diabetes Care, 2010, 33, 2561-2566.	8.6	53
126	Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy. Diabetes Care, 2010, 33, 1567-1572.	8.6	98

#	Article	IF	Citations
127	Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes, 2010, 59, 2027-2032.	0.6	109
128	Vitamin D Levels and Mortality in Type 2 Diabetes. Diabetes Care, 2010, 33, 2238-2243.	8.6	126
129	Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets, 2010, 21, 525-532.	2.3	30
130	A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes. PLoS Genetics, 2010, 6, e1000842.	3.5	81
131	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437.	3.8	434
132	Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition. Diabetes Care, 2009, 32, 1684-1688.	8.6	64
133	Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ: British Medical Journal, 2009, 339, b4324-b4324.	2.3	32
134	YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria. Diabetes Care, 2009, 32, 323-328.	8.6	117
135	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia, 2009, 52, 46-49.	6.3	32
136	The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes. Diabetologia, 2009, 52, 2590-2593.	6.3	45
137	Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus. BMC Medical Genomics, 2009, 2, 41.	1.5	11
138	Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy Trial. Diabetes, Obesity and Metabolism, 2009, 11, 315-322.	4.4	26
139	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2009, 11, 966-977.	4.4	42
140	Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes. Diabetes, 2009, 58, 1668-1671.	0.6	194
141	Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. Diabetes Research and Clinical Practice, 2009, 84, 34-38.	2.8	8
142	The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Molecular Genetics and Metabolism, 2009, 97, 80-84.	1.1	37
143	Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets, 2009, 20, 513-519.	2.3	28
144	Long-term prevention of diabetic nephropathy: an audit. Diabetologia, 2008, 51, 956-961.	6.3	24

#	Article	IF	Citations
145	Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia, 2008, 51, 2100-2107.	6.3	70
146	Elevated Levels of High-Molecular-Weight Adiponectin in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3186-3191.	3.6	71
147	G/T Substitution in Intron 1 of the UNC13B Gene Is Associated With Increased Risk of Nephropathy in Patients With Type 1 Diabetes. Diabetes, 2008, 57, 2843-2850.	0.6	39
148	A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 654-659.	1.2	50
149	The PPARÎ³2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Molecular Genetics and Metabolism, 2008, 94, 347-351.	1.1	24
150	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney International, 2008, 73, 1419-1425.	5.2	121
151	Identification of a xylosyltransferase II gene haplotype marker for diabetic nephropathy in type 1 diabetes. Clinica Chimica Acta, 2008, 398, 90-94.	1.1	14
152	Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. European Journal of Endocrinology, 2008, 158, 443-445.	3.7	2
153	Relation of Left Ventricular Function, Mass, and Volume to NT-proBNP in Type 1 Diabetic Patients. Diabetes Care, 2008, 31, 968-970.	8.6	5
154	Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2008, 31, 747-752.	8.6	121
155	Comment on: Wanic et al. (2008) Exclusion of Polymorphisms in Carnosinase Genes (CNDP1 and) Tj ETQq1 1 0.784314 rgBT /O Follow-Up Studies: Diabetes 57:2547â€“2551, 2008. Diabetes, 2008, 57, e16-e16.	0.6	4
156	Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years. Diabetes Care, 2008, 31, 1170-1176.	8.6	106
157	Plasma Connective Tissue Growth Factor Is an Independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy. Diabetes Care, 2008, 31, 1177-1182.	8.6	99
158	Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. European Journal of Endocrinology, 2008, 158, 35-46.	3.7	26
159	Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. European Journal of Endocrinology, 2008, 158, 631-641.	3.7	84
160	Urinary Proteomics in Diabetes and CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1283-1290.	6.1	267
161	Plasma Î±-Defensin Is Associated with Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1470-1475.	3.6	41
162	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney International, 2008, 74, 649-654.	5.2	124

#	Article	IF	Citations
163	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 731-738.	1.2	74
164	Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. PLoS ONE, 2008, 3, e3363.	2.5	83
165	Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrology Dialysis Transplantation, 2007, 22, 3235-3239.	0.7	15
166	European rational approach for the genetics of diabetic complications EURAGEDIC: patient populations and strategy. Nephrology Dialysis Transplantation, 2007, 23, 161-168.	0.7	30
167	Subclinical Coronary and Aortic Atherosclerosis Detected by Magnetic Resonance Imaging in Type 1 Diabetes With and Without Diabetic Nephropathy. Circulation, 2007, 115, 228-235.	1.6	111
168	Association between Angiotensin-Converting Enzyme Gene Polymorphisms and Diabetic Nephropathy: Case-Control, Haplotype, and Family-Based Study in Three European Populations. Journal of the American Society of Nephrology: JASN, 2007, 18, 1284-1291.	6.1	64
169	An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. European Journal of Endocrinology, 2007, 156, 83-90.	3.7	10
170	Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obesity and Metabolism, 2007, 9, 394-407.	4.4	40
171	CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabetic Medicine, 2007, 24, 323-325.	2.3	14
172	Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in TypeÂ2 diabetes. Diabetic Medicine, 2007, 24, 969-976.	2.3	81
173	Pregnancy-associated plasma proteinÂA in a large cohort of TypeÂ1 diabetic patients with and without diabetic nephropathyâ€"a prospective follow-up study. Diabetic Medicine, 2007, 24, 1381-1385.	2.3	12
174	Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabetic Medicine, 2006, 23, 675-680.	2.3	7
175	Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?. Kidney International, 2006, 69, 1293-1295.	5.2	20
176	Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International, 2006, 70, 536-542.	5.2	189
177	Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia, 2006, 49, 2256-2262.	6.3	96
178	Mannose-Binding Lectin and Mortality in Type 2 Diabetes. Archives of Internal Medicine, 2006, 166, 2007.	3.8	79
179	Analysis of 14 Candidate Genes for Diabetic Nephropathy on Chromosome 3q in European Populations. Diabetes, 2006, 55, 3166-3174.	0.6	74
180	Aldosterone synthase (CYP11B2)Â344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. Scandinavian Journal of Clinical and Laboratory Investigation, 2006, 66, 173-180.	1.2	6

#	Article	IF	Citations
181	Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. Diabetes, 2006, 55, 3550-3555.	0.6	77
182	Cardiac Autonomic Neuropathy Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2006, 29, 334-339.	8.6	156
183	Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. European Journal of Endocrinology, 2006, 154, 75-81.	3.7	132
184	The Xylosyltransferase I Gene Polymorphism c.343G>T (p.A125S) Is a Risk Factor for Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2006, 29, 2295-2299.	8.6	10
185	Urinary Connective Tissue Growth Factor Excretion Correlates With Clinical Markers of Renal Disease in a Large Population of Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2006, 29, 83-88.	8.6	52
186	Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney International, 2005, 67, 2325-2329.	5.2	41
187	Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study. Kidney International, 2005, 68, 1250-1257.	5.2	70
188	Impact of polymorphisms in the genes encoding xylosyltransferase I and a homologue in type 1 diabetic patients with and without nephropathy. Kidney International, 2005, 68, 1483-1490.	5.2	15
189	Beneficial impact of spironolactone in diabetic nephropathy. Kidney International, 2005, 68, 2829-2836.	5.2	201
190	Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia, 2005, 48, 198-202.	6.3	85
191	Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia, 2005, 48, 149-155.	6.3	58
192	The prevalence of coeliac disease in adult Danish patients with type 1 diabetes with and without nephropathy. Diabetologia, 2005, 48, 1416-1417.	6.3	23
193	Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia, 2005, 48, 1911-1918.	6.3	210
194	Mannose-Binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes. Diabetes, 2005, 54, 1523-1527.	0.6	111
195	Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 879-884.	0.5	19
196	PGC-1Î± Gly482Ser Polymorphism Associates With Hypertension Among Danish Whites. Hypertension, 2005, 45, 565-570.	2.7	42
197	Elevated Placental Growth Factor (PlGF) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients with Diabetic Nephropathy. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 73-79.	1.2	15
198	Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrology Dialysis Transplantation, 2004, 19, 2784-2788.	0.7	188

#	Article	IF	Citations
199	Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabetic Medicine, 2004, 21, 867-873.	2.3	24
200	Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney International, 2004, 66, 1180-1186.	5.2	40
201	Progression of nephropathy in type 2 diabetic patients. Kidney International, 2004, 66, 1596-1605.	5.2	270
202	Aldosterone escape during blockade of the renin?angiotensin?aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia, 2004, 47, 1936-1939.	6.3	214
203	Remission and regression of diabetic nephropathy. Current Hypertension Reports, 2004, 6, 377-382.	3.5	23
204	Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ: British Medical Journal, 2004, 328, 1105.	2.3	337
205	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminars in Nephrology, 2004, 24, 147-157.	1.6	57
206	Elevated Plasma Asymmetric Dimethylarginine as a Marker of Cardiovascular Morbidity in Early Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2004, 27, 765-769.	8.6	180
207	Association Between Mannose-Binding Lectin and Vascular Complications in Type 1 Diabetes. Diabetes, 2004, 53, 1570-1576.	0.6	161
208	Birth weight - a risk factor for progression in diabetic nephropathy?. Journal of Internal Medicine, 2003, 253, 343-350.	6.0	16
209	Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy. Diabetes Care, 2003, 26, 1501-1506.	8.6	60
210	Smoking and Progression of Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2003, 26, 911-916.	8.6	52
211	Decreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes. Diabetes Care, 2003, 26, 1258-1264.	8.6	325
212	Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 2843-2850.	6.1	83
213	Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 293-297.	0.7	21
214	Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?. Kidney International, 2002, 62, 192-198.	5.2	30
215	Total plasma homocysteine is associated with hypertension in Type I diabetic patients. Diabetologia, 2002, 45, 1315-1324.	6.3	30
216	Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1. American Journal of Kidney Diseases, 2001, 38, 1376-1380.	1.9	27

#	Article	IF	Citations
217	Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively11See Editorial by Steffes, p. 378. Kidney International, 2001, 60, 277-283.	5.2	89
218	Progression of diabetic nephropathy. Kidney International, 2001, 59, 702-709.	5.2	283
219	Preventing diabetic nephropathy: an audit. Scandinavian Journal of Clinical and Laboratory Investigation, 2001, 61, 471-477.	1.2	5
220	Remission of Nephrotic-Range Albuminuria in Type 1 Diabetic Patients. Diabetes Care, 2001, 24, 1972-1977.	8.6	63
221	Plasminogen activator inhibitorâ€1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrology Dialysis Transplantation, 2000, 15, 625-630.	0.7	53
222	Genetic polymorphisms of the reninâ€“angiotensin system and complications of insulinâ€dependent diabetes mellitus. Nephrology Dialysis Transplantation, 2000, 15, 1000-1007.	0.7	69
223	Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney International, 2000, 57, 601-606.	5.2	250
224	Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney International, 2000, 57, S56-S61.	5.2	101
225	Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients. Diabetologia, 2000, 43, 794-799.	6.3	29
226	Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 2000, 23, 30-33.	8.6	53
227	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney International, 1999, 56, S101-S105.	5.2	80
228	Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy. Diabetologia, 1999, 42, 76-80.	6.3	33
229	Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries.. Diabetes, 1999, 48, 2446-2453.	0.6	143
230	Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrology Dialysis Transplantation, 1999, 14, 1904-1911.	0.7	58
231	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney International, 1998, 53, 1002-1006.	5.2	91
232	Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes, 1998, 47, 439-444.	0.6	74
233	Meta analysis. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrology Dialysis Transplantation, 1998, 13, 1125-1130.	0.7	68
234	Genetic Variation of a Collagen IV Î±1-Chain Gene Polymorphism in Danish Insulin-dependent Diabetes Mellitus (IDDM) Patients: Lack of Association to Nephropathy and Proliferative Retinopathy. , 1997, 14, 143-147.		9

#	Article	IF	Citations
235	Angiotensinogen Gene Polymorphisms in IDDM Patients With Diabetic Nephropathy. Diabetes, 1996, 45, 367-369.	0.6	63
236	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. Nephrology Dialysis Transplantation, 1996, 11, 1019-1023.	0.7	36
237	Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ: British Medical Journal, 1996, 313, 591-594.	2.3	158
238	Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia, 1995, 38, 798-803.	6.3	87
239	Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy?. Diabetes, 1995, 44, 1405-1407.	0.6	77
240	Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin Iâ€“Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients. Diabetes, 1995, 44, 489-494.	0.6	184
241	Short stature and diabetic nephropathy. BMJ: British Medical Journal, 1995, 310, 296-297.	2.3	55
242	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes, 1995, 44, 489-494.	0.6	70
243	Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V. Diabetes Care, 1994, 17, 1247-1251.	8.6	162